^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ABP 206 (nivolumab biosimilar)
i
Other names: ABP 206, ABP-206, ABP206
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Amgen
Drug class:
PD1 inhibitor
Related drugs:
15h
NCI-2018-01560: Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma (clinicaltrials.gov)
P1/2, N=38, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Mar 2027 | Trial primary completion date: Jan 2026 --> Mar 2027
Trial completion date • Trial primary completion date • Tumor mutational burden
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
6d
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer (clinicaltrials.gov)
P1, N=33, Not yet recruiting, City of Hope Medical Center | Initiation date: Dec 2025 --> Apr 2026
Trial initiation date
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
11d
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (clinicaltrials.gov)
P2, N=40, Recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2029 --> Sep 2031 | Trial primary completion date: Sep 2029 --> Sep 2031
Trial completion date • Trial primary completion date
|
IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
|
Opdivo (nivolumab) • capecitabine • Jelmyto (mitomycin urothelial gel) • fluorouracil topical • ABP 206 (nivolumab biosimilar)
12d
A091902: Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma (clinicaltrials.gov)
P2, N=89, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2026 --> Jan 2027 | Trial primary completion date: Sep 2026 --> Mar 2025
Trial completion date • Trial primary completion date
|
Opdivo (nivolumab) • paclitaxel • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
12d
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery (clinicaltrials.gov)
P2, N=99, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
13d
NCI10208: Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer (clinicaltrials.gov)
P1, N=74, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
Trial completion date • Trial primary completion date • Tumor mutational burden • IO biomarker
|
MSLN (Mesothelin)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • gemcitabine • anetumab ravtansine (BAY 94-9343) • ABP 206 (nivolumab biosimilar)
19d
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (clinicaltrials.gov)
P2/3, N=600, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
Enrollment closed
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF wild-type
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar) • Leukine (sargramostim)
22d
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma (clinicaltrials.gov)
P3, N=633, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting
Enrollment closed
|
Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar)
26d
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (clinicaltrials.gov)
P3, N=636, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
Enrollment closed • Tumor mutational burden • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab) • cisplatin • ABP 206 (nivolumab biosimilar)
1m
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative (clinicaltrials.gov)
P2/3, N=427, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
Trial suspension
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
PD-L1 expression • ALK mutation
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • paclitaxel • ABP 206 (nivolumab biosimilar)
1m
Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome (clinicaltrials.gov)
P1, N=38, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2027 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
Opdivo (nivolumab) • Copiktra (duvelisib) • ABP 206 (nivolumab biosimilar) • ETP-47187
1m
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis (clinicaltrials.gov)
P1, N=15, Recruiting, Mayo Clinic | Trial completion date: Jan 2026 --> Apr 2030 | Trial primary completion date: Jan 2026 --> Apr 2027
Trial completion date • Trial primary completion date
|
Opdivo (nivolumab) • oxaliplatin • leucovorin calcium • Proleukin (aldesleukin) • fluorouracil topical • ABP 206 (nivolumab biosimilar)
Share via
